Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE2A | O00408 | 13/20 | 0.35 |
| ▸ | CNR2 | P34972 | 1/20 | 0.35 |
| ▸ | EEF2K | O00418 | 1/20 | 0.33 |
| ▸ | GPR139 | Q6DWJ6 | 1/20 | 0.33 |
| ▸ | CYP26A1 | O43174 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2549581 | 1.00 | PDE2A (0.35) | PDE2ACNR2EEF2KGPR139CYP26A1 | |
| SCHEMBL1595429 | 0.81 | PDE2A (0.39) | PDE2ACNR2EEF2K | |
| SCHEMBL1595431 | 0.81 | PDE2A (0.39) | PDE2ACNR2EEF2K | |
| SCHEMBL1743596 | 0.81 | TRPV1 (0.36) | PDE2ACNR2CYP3A4 | |
| SCHEMBL1596369 | 0.81 | PDE2A (0.37) | PDE2ACNR2 | |
| SCHEMBL2548062 | 0.78 | CES2 (0.32) | EEF2KCYP26A1CYP3A4 | |
| SCHEMBL1741901 | 0.78 | PPARA (0.41) | PDE2ACNR2CYP3A4 | |
| SCHEMBL1741902 | 0.78 | PPARA (0.41) | PDE2ACNR2CYP3A4 | |
| SCHEMBL5018934 | 0.77 | AKR1C3 (0.39) | PDE2ACNR2EEF2KCYP26A1 | |
| SCHEMBL1744761 | 0.77 | CNR2 (0.34) | PDE2ACNR2EEF2K |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2387570-A1 | FLUOROISOQUINOLINE SUBSTITUTED THIAZOLE COMPOUNDS AND METHODS OF USE | Amgen, Inc (US) | 2011-11-23 | — | — | EP | disclosed |
| US-20110263647-A1 | FLUOROISOQUINOLINE SUBSTITUTED THIAZOLE COMPOUNDS AND METHODS OF USE | AMGEN INC. (US) | 2011-10-27 | — | — | US | disclosed |
| WO-2010083246-A1 | FLUOROISOQUINOLINE SUBSTITUTED THIAZOLE COMPOUNDS AND METHODS OF USE | AMGEN INC. (US) | 2010-07-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110263647-A1 | FLUOROISOQUINOLINE SUBSTITUTED THIAZOLE COMPOUNDS AND METHODS OF USE | TFEB, PCK2, JAK2 | PDE2A 2083/4885CNR2 2228/4885EEF2K 48/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.